Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	11	8	13	37	66	-
Market Cap Growth	-26.58%	-37.83%	-65.89%	-44.21%	-	-
Enterprise Value	2	-5	-10	-4	53	0
PE Ratio	-	-0.41	-0.70	-2.50	-23.27	-
PS Ratio	55.23	30.10	102.18	11.93	94.89	-
PB Ratio	1.60	0.71	0.60	0.96	6.77	-
P/FCF Ratio	-0.87	-0.43	-0.72	-2.59	-58.69	-
P/OCF Ratio	-0.88	-0.43	-0.73	-2.59	-58.69	-
EV/Sales Ratio	7.99	-18.38	-83.37	-1.14	75.37	0.32
EV/EBITDA Ratio	-0.24	0.25	0.57	0.24	-18.68	-0.06
EV/EBIT Ratio	-0.24	0.25	0.57	0.24	-18.68	-0.06
EV/FCF Ratio	-0.30	0.26	0.58	0.25	-46.61	-1.05
Debt / Equity Ratio	0.07	0.06	0.01	0.01	0.03	-0.08
Debt / EBITDA Ratio	-0.03	-0.03	-0.01	-0.02	-0.11	-0.07
Debt / FCF Ratio	-0.03	-0.03	-0.01	-0.02	-0.28	-1.10
Quick Ratio	2.30	3.85	6.25	10.08	2.96	0.00
Current Ratio	2.55	4.13	6.60	10.48	3.13	0.01
Asset Turnover	0.01	0.01	0.00	0.08	0.09	0.78
Interest Coverage	-	-	-	-741.16	-95.86	-229.44
Return on Equity (ROE)	-147.00%	-107.50%	-65.80%	-43.30%	-107.60%	217.30%
Return on Assets (ROA)	-116.70%	-91.80%	-57.40%	-39.60%	-38.40%	-396.80%
Return on Capital (ROIC)	-277.39%	-173.19%	-85.59%	-38.19%	-27.90%	138.43%
Earnings Yield	-177.39%	-242.67%	-143.13%	-39.99%	-4.30%	-
FCF Yield	-147.76%	-230.82%	-139.49%	-38.66%	-1.70%	-
Buyback Yield / Dilution	-38.29%	-26.28%	-39.15%	-121.72%	-0.39%	-2.08%
Total Shareholder Return	-38.29%	-26.28%	-39.15%	-121.72%	-0.39%	-2.08%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).